## Contents

**EDITORIAL**

1384  Hepatocellular adenoma: Where are we now?

*Wang X, Zhang X*

**OPINION REVIEW**

1394  Endoluminal vacuum-assisted therapy to treat rectal anastomotic leakage: A critical analysis

*Vignali A, De Nardi P*

**REVIEW**

1405  Viral hepatitis: Past, present, and future

*Odenwald MA, Paul S*

1430  Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges

*Pugliese N, Arcari I, Aghemo A, Lania AG, Lleo A, Mazziotti G*

**ORIGINAL ARTICLE**

**Basic Study**

1444  Syngeneic implantation of mouse hepatic progenitor cell-derived three-dimensional liver tissue with dense collagen fibrils

*Tamai M, Adachi E, Kawase M, Tagawa YI*

**Retrospective Cohort Study**

1455  Clinical classification of symptomatic heterotopic pancreas of the stomach and duodenum: A case series and systematic literature review

*LeCompte MT, Mason B, Robbins KJ, Yano M, Chatterjee D, Fields RC, Strasberg SM, Hawkins WG*

**Retrospective Study**

1479  Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma

*Che F, Xu Q, Li Q, Huang ZX, Yang CW, Wang LY, Wei Y, Shi YJ, Song B*

**LETTER TO THE EDITOR**

1494  Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients

*Bouare N, Keita M, Delwaide J*

1499  Comments on “Effect of type 2 diabetes mellitus in the prognosis of acute-on-chronic liver failure patients in China”

*Wang W, Pan CC, Zhao WY, Sheng JY, Wu QQ, Chen SS*
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Sung-Chul Lim, MD, PhD, Professor, Head, Department of Pathology, Chosun University Hospital, 365 Pilmun-daero, Dong-gu, Gwangju 61453, South Korea. sclim@chosun.ac.kr

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xu Gu; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
April 14, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.ffipublishing.com
Comments on “Effect of type 2 diabetes mellitus in the prognosis of acute-on-chronic liver failure patients in China”

Wei Wang, Chen-Chen Pan, Wen-Ying Zhao, Jin-Yu Sheng, Qi-Qi Wu, Si-Si Chen

Abstract

A study addressing the influence of type 2 diabetes on the prognosis of acute-on-chronic liver failure patients was reviewed. Some statistical deficiencies were found in the reviewed article, and the sample size was too small to support the study. In addition, age should have been considered as one of the prognostic factors.

Key Words: Type 2 diabetes mellitus; Liver failure; Complication; Prognosis; Age

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This is a comment on a study of the influence of type 2 diabetes on the prognosis of patients with acute-on-chronic liver failure. We believe that the conclusion of this study can provide more significant data.

Citation: Wang W, Pan CC, Zhao WY, Sheng JY, Wu QQ, Chen SS. Comments on “Effect of type 2 diabetes mellitus in the prognosis of acute-on-chronic liver failure patients in China”. World J Gastroenterol 2022; 28(14): 1499-1502

URL: https://www.wjgnet.com/1007-9327/full/v28/i14/1499.htm

TO THE EDITOR

We were pleased to read the high-level article published by Lai et al.[1]. The results of their study showed a significant relationship between the prognosis of diabetes mellitus (DM) and acute-on-chronic liver failure (ACLF) patients. ACLF patients with DM have higher in-hospital mortality and infection rates than patients without DM. This is an important study that has made a significant contribution to the study of prognostic indicators for ACLF patients. However, there are still questionable issues in this study that we would like to discuss with the authors.

First, the Materials and Methods section needs to be more detailed and refined. The author should list the number of diabetic patients included and the number of people after grouping. The author should state the time for follow-up of the patients and redefine the concept of follow-up. If the author regards the discharge time as the end of the follow-up event, it may cause data loss. Therefore, another reference could be added for loss to follow-up. We notice that they performed multivariate analysis on parameters with $P < 0.1$ in univariate analysis, which is not convincing. A $P$ value less than 0.05 would make the results more convincing. In addition, a sample of 200 for a study period of 7 years is small; the author should calculate the population size and analyze the sample size.

There are problems in the statistical analyses. Statistical analyses should be described in detail. In the table in the Results section, the author should provide more accurate statistical values, such as Student’s $t$-values or $\chi^2$ values. Table 1 shows that there are statistical differences in age between the DM group and non-DM group. Therefore, the author should describe the frequency and distribution of age in more detail and discuss the possible impact of age as a potential risk factor on the disease. For example, the author could divide the patients into different levels in the DM and non-DM groups according to age and statistically analyze the impact of different ages in each level on the mortality and infection rate of related diseases. According to the criteria of the World Health Organization in 2012[1,2], a younger age was defined as less than 45 years, and an older age was defined as greater or equal to 45 years. Therefore, the author could divide the original two groups into four groups. In Figure 1 (Figure in the manuscript “Effect of type 2 diabetes mellitus in the prognosis of acute-on-chronic liver failure patients in China”[1]), the author should indicate the time unit. We do not know how long the patients lived. In addition, we also noticed that the author did not indicate the corresponding $P$ value when stating some conclusions.

In the paper, the author repeatedly proposed that DM could predict ACLF. This is a confusing statement. The study only proves that DM has a certain influence on ACLF. To further predict ACLF through DM, a survival model would need to be established. The author should provide more detailed data, such as median follow-up and survival times, to build up the survival model.

In the Discussion section, the author explained that albumin (ALB) has nothing to do with the prognosis of liver failure in this study and believed that exogenous injection of ALB interfered with the experimental results. Inferring from this, we believe that the author neglected interference caused by the patients’ medications on the experimental results during treatment. ALB constitutes about half of serum proteins. ALB is involved in scavenging free radicals, maintaining colloidal osmotic pressure and protecting neuronal cells and is closely related to nutritional level[3] and systemic inflammatory...
Table 1 Demographic characteristics and clinical features of the patients between diabetic mellitus and non-diabetic mellitus[1]

<table>
<thead>
<tr>
<th></th>
<th>DM (yes) (n = 38)</th>
<th>DM (no) (n = 184)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>56.32 ± 14.23</td>
<td>49.16 ± 12.84</td>
<td>0.002</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td>0.309</td>
</tr>
<tr>
<td>Male</td>
<td>28 (73.68)</td>
<td>149 (80.98)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>10 (26.32)</td>
<td>35 (19.02)</td>
<td></td>
</tr>
<tr>
<td>Cause of disease, n (%)</td>
<td></td>
<td></td>
<td>0.201</td>
</tr>
<tr>
<td>Hepatitis B virus</td>
<td>26 (68.42)</td>
<td>139 (75.54)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B virus + other</td>
<td>5 (13.16)</td>
<td>20 (10.87)</td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>2 (5.26)</td>
<td>15 (8.15)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>5 (13.16)</td>
<td>10 (5.44)</td>
<td></td>
</tr>
<tr>
<td>WBC (10^9/L)</td>
<td>6.17 ± 4.03</td>
<td>7.35 ± 3.58</td>
<td>0.07</td>
</tr>
<tr>
<td>RBC (10^12/L)</td>
<td>3.68 ± 0.87</td>
<td>3.94 ± 0.84</td>
<td>0.084</td>
</tr>
<tr>
<td>Hb (g/L)</td>
<td>117.21 ± 24.71</td>
<td>121.95 ± 23.13</td>
<td>0.257</td>
</tr>
<tr>
<td>PLT (10^9/L)</td>
<td>100.34 ± 42.20</td>
<td>118.79 ± 59.09</td>
<td>0.069</td>
</tr>
<tr>
<td>PT (s)</td>
<td>23.01 ± 5.38</td>
<td>24.45 ± 6.95</td>
<td>0.229</td>
</tr>
<tr>
<td>INR</td>
<td>1.97 ± 0.45</td>
<td>2.10 ± 0.59</td>
<td>0.229</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>396.08 ± 448.56</td>
<td>560.36 ± 693.06</td>
<td>0.163</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>365.93 ± 391.18</td>
<td>419.99 ± 513.42</td>
<td>0.541</td>
</tr>
<tr>
<td>γ-GGT (U/L)</td>
<td>174.16 ± 305.61</td>
<td>137.57 ± 127.33</td>
<td>0.231</td>
</tr>
<tr>
<td>TBIL (μmol/L)</td>
<td>320.71 ± 141.31</td>
<td>309.56 ± 134.00</td>
<td>0.664</td>
</tr>
<tr>
<td>ALB (g/L)</td>
<td>29.25 ± 4.51</td>
<td>30.73 ± 4.03</td>
<td>0.045</td>
</tr>
<tr>
<td>Scr (μmol/L)</td>
<td>56.37 ± 22.00</td>
<td>63.45 ± 27.28</td>
<td>0.134</td>
</tr>
<tr>
<td>BUN (mmol/L)</td>
<td>3.94 ± 2.65</td>
<td>4.25 ± 2.98</td>
<td>0.56</td>
</tr>
<tr>
<td>TCHO (mmol/L)</td>
<td>2.67 ± 0.81</td>
<td>2.65 ± 1.05</td>
<td>0.919</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.45 ± 0.67</td>
<td>1.26 ± 0.70</td>
<td>0.124</td>
</tr>
<tr>
<td>Na⁺ (mmol/L)</td>
<td>136.98 ± 3.97</td>
<td>136.86 ± 4.43</td>
<td>0.878</td>
</tr>
<tr>
<td>K⁺ (mmol/L)</td>
<td>3.90 ± 0.46</td>
<td>4.08 ± 0.58</td>
<td>0.072</td>
</tr>
<tr>
<td>AMON (μmol/L)</td>
<td>3.90 ± 0.46</td>
<td>4.08 ± 0.58</td>
<td>0.332</td>
</tr>
<tr>
<td>AFP (ng/mL)</td>
<td>64.40 ± 40.39</td>
<td>128.19 ± 192.02</td>
<td>0.784</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.99 ± 3.32</td>
<td>22.78 ± 3.03</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>FRG (mmol/L)</td>
<td>5.34 ± 1.87</td>
<td>3.83 ± 1.07</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Scoring systems</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTP</td>
<td>10.79 ± 1.49</td>
<td>10.40 ± 1.35</td>
<td>0.115</td>
</tr>
<tr>
<td>MELD</td>
<td>19.38 ± 4.52</td>
<td>20.74 ± 5.06</td>
<td>0.128</td>
</tr>
<tr>
<td>MELD-Na</td>
<td>20.89 ± 5.00</td>
<td>22.27 ± 6.84</td>
<td>0.239</td>
</tr>
<tr>
<td>Death, n (%)</td>
<td>25 (65.79)</td>
<td>69 (37.5)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

response[4]. The author should describe in detail in the Methods section the type, dosage and method of drug injection during the treatment process. Actually, well-established indications for the use of human ALB in patients with cirrhosis pertain to conditions that are characterized by an acute deterioration of effective hypovolemia[5], such as renal dysfunction secondary to spontaneous bacterial peritonitis and hepatorenal syndrome, as shown by the international guidelines on the management of decompensated cirrhosis[6]. The current established indications for ALB use in patients with cirrhosis, such as preventing renal dysfunction induced by systolic blood pressure, suggest that patients should receive 1.5 g/kg body weight at diagnosis +1 g/kg body weight at day 3[7].

All in all, this is a high-level article in the field of diabetes and liver cirrhosis. Although there are some statistical deficiencies in the article, the author may be able to expand the sample and establish a multicenter prospective cohort study. For example, age factors could be considered for related diseases to evaluate the impact of DM on the prognosis in ACLF patients.

FOOTNOTES

Author contributions: Wang W and Chen SS contributed equally to this work; Wang W, Chen SS, Pan CC, Zhao WY, Sheng JY and Wu QQ designed the research study; Wang W, Chen SS, Pan CC and Zhao WY performed the research; Wang W and Chen SS contributed to new reagents and analytic tools; Wang W, Pan CC and Zhao WY analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.

Conflict-of-interest statement: Each author has reviewed the statement by the Baishideng Publishing Group on conflict of interest, and every author stated that there is no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Wei Wang 0000-0001-5630-3287; Chen-Chen Pan 0000-0001-8234-6870; Wen-Ying Zhao 0000-0002-8190-2561; Jin-Yu Sheng 0000-0002-6132-4637; Qi-Qi Wu 0000-0002-4997-1022; Si-Si Chen 0000-0003-0125-8022.

S-Editor: Fan JR
L-Editor: Filipodia
P-Editor: Fan JR

REFERENCES
